


IRON DEFICIENCY AND ANEMIA

Diagnosis



Correction of Iron Deficiency*

Europe & Australia

Ferric carboxymaltose dosage forms:

- 100 mg
- 500 mg
- 1,000 mg

Hemoglobin		Patient body weight		
g/dL	mmol/L	<35 kg	35 kg – <70 kg	≥70 kg
<10	<6.2	500 mg	1500 mg	2000 mg
10-14	6.2–8.7	500 mg	1000 mg	1500 mg
>14	>8.7	500 mg	500 mg	500 mg

United States

Ferric carboxymaltose dosage form:

- 750 mg iron per 15 mL vial
- Patients weighing ≥50 kg (≥110 lbs)
- 2x 750 mg (1500 mg total)
 - Separated by at least 7 days
- Patients weighing <50 kg (<110 lbs)
- 2x 15 mg/kg body weight
 - Separated by at least 7 days

*Oral iron is insufficient for the correction of iron deficiency in patients with heart failure.

Monitoring



Check ferritin + TSAT

at next scheduled visit (preferably at 3 months)



Check ferritin + TSAT

1-2 times per year or if change in clinical picture or if hemoglobin decreases

Ferric carboxymaltose. Package leaflet. Vifor France; 2020.

Ferric carboxymaltose. Australian product information. Vifor Pharma Pty Ltd; 2020.

Lewis GD, et al. *JAMA*. 2017;317(19):1958-1966.

McDonagh T, et al. *Eur J Heart Fail*. 2018;20(12):1664-1672.

NHFA CSANZ Heart Failure Guidelines Working Group, et al. *Heart Lung Circ*. 2018;27(10):1123-1208.

Ponikowski P, et al. *Eur J Heart Fail*. 2016;37(27):2129-2200.

Yancy CW, et al. *J Am Coll Cardiol*. 2017;70(6):776-803.